NASDAQ:ALLO Allogene Therapeutics (ALLO) Stock Price, News & Analysis → Biden FINISHED On June 13th? (From Paradigm Press) (Ad) Free ALLO Stock Alerts $2.96 +0.06 (+2.07%) (As of 05/14/2024 ET) Add Compare Share Share Today's Range$2.72▼$3.6550-Day Range$2.76▼$5.6352-Week Range$2.23▼$6.89Volume8.48 million shsAverage Volume2.50 million shsMarket Capitalization$505.33 millionP/E RatioN/ADividend YieldN/APrice Target$13.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Allogene Therapeutics alerts: Email Address Allogene Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside313.1% Upside$12.23 Price TargetShort InterestBearish32.03% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.31Based on 17 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.65) to ($1.69) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.71 out of 5 starsMedical Sector1998th out of 2,771 stocksBiological Products, Except Diagnostic Industry340th out of 462 stocks 3.3 Analyst's Opinion Consensus RatingAllogene Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageAllogene Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Allogene Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted32.03% of the float of Allogene Therapeutics has been sold short.Short Interest Ratio / Days to CoverAllogene Therapeutics has a short interest ratio ("days to cover") of 15.5, which indicates bearish sentiment.Change versus previous monthShort interest in Allogene Therapeutics has recently increased by 8.00%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAllogene Therapeutics does not currently pay a dividend.Dividend GrowthAllogene Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALLO. Previous Next 2.4 News and Social Media Coverage News SentimentAllogene Therapeutics has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Allogene Therapeutics this week, compared to 3 articles on an average week.Search Interest8 people have searched for ALLO on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Allogene Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders24.30% of the stock of Allogene Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.63% of the stock of Allogene Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Allogene Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Allogene Therapeutics are expected to decrease in the coming year, from ($1.65) to ($1.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allogene Therapeutics is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Allogene Therapeutics is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAllogene Therapeutics has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Allogene Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden to Drop BOMBSHELL June 13th?Biden’s days are numbered! According to a former CIA and Pentagon insider… He’s about to drop out of the presidential race on June 13th!Click here now to see his shocking evidence. About Allogene Therapeutics Stock (NASDAQ:ALLO)Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Read More ALLO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALLO Stock News HeadlinesMay 14 at 6:32 PM | markets.businessinsider.comAllogene Therapeutics: Strategic Expansion and Promising Trial Outcomes Bolster Buy RatingMay 14 at 2:46 AM | msn.comAllogene Therapeutics GAAP EPS of -$0.38 beats by $0.03May 14 at 2:46 AM | markets.businessinsider.comAllogene Therapeutics (ALLO) Receives a Buy from TD CowenMay 14 at 2:46 AM | finance.yahoo.comAllogene Therapeutics Reports First Quarter 2024 Financial Results and Business UpdateMay 13 at 9:30 PM | investorplace.comALLO Stock Earnings: Allogene Therapeutics Beats EPS, Beats Revenue for Q1 2024May 13 at 4:47 PM | globenewswire.comAllogene Therapeutics Announces Pricing of $110 million Offering of Common StockMay 13 at 4:01 PM | globenewswire.comAllogene Therapeutics Reports First Quarter 2024 Financial Results and Business UpdateMay 12 at 10:10 AM | markets.businessinsider.comAllogene Therapeutics earnings: here's what Wall Street expectsMay 11 at 1:44 AM | americanbankingnews.comAllogene Therapeutics (ALLO) to Release Quarterly Earnings on MondayMay 7, 2024 | americanbankingnews.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Rating of "Moderate Buy" from BrokeragesMay 6, 2024 | globenewswire.comAllogene Therapeutics to Report First Quarter Financial Results and Provide Business UpdateMay 2, 2024 | seekingalpha.comALLO Allogene Therapeutics, Inc.April 26, 2024 | globenewswire.comAllogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell CarcinomaApril 18, 2024 | benzinga.comTo The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation - Allogene Therapeutics (NASDAQ:ALLO), ARK Innovation ETF (ARCA:ARKK)April 11, 2024 | investorplace.com3 Meme Stocks to Sell and Replace With Meme CoinsApril 9, 2024 | globenewswire.comAllogene Therapeutics Announces Q2 Investor Conference ParticipationApril 1, 2024 | seekingalpha.comAllogene Therapeutics: 2024 Platform Vision Sings Mid-Term UpsideMarch 20, 2024 | markets.businessinsider.comStifel Nicolaus Sticks to Their Hold Rating for Allogene Therapeutics (ALLO)March 19, 2024 | markets.businessinsider.comAllogene Therapeutics Poised for Growth: A Strong Buy Rating Amidst Innovative Trials and Strategic AdvancementsMarch 18, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Black Diamond Therapeutics (BDTX) and I-MAB (IMAB)March 16, 2024 | finance.yahoo.comAllogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | finanznachrichten.deAllogene Therapeutics, Inc.: Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdateMarch 15, 2024 | markets.businessinsider.comAllogene Therapeutics: Redefining LBCL Treatment with Innovative ALPHA3 Trial and Promising Cema-cel TherapyMarch 15, 2024 | markets.businessinsider.comAllogene Therapeutics: Advancing Clinical Studies and Promising Treatment Differentiation Set Stage for Stock Value GrowthMarch 14, 2024 | investorplace.comALLO Stock Earnings: Allogene Therapeutics Misses EPS, Beats Revenue for Q4 2023See More Headlines Receive ALLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today5/14/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ALLO CUSIPN/A CIK1737287 Webwww.allogene.com Phone(650) 457-2700FaxN/AEmployees232Year Founded2018Price Target and Rating Average Stock Price Target$12.23 High Stock Price Target$28.00 Low Stock Price Target$4.60 Potential Upside/Downside+365.5%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-327,270,000.00 Net Margins-202,366.25% Pretax Margin-344,489.50% Return on Equity-53.76% Return on Assets-43.24% Debt Debt-to-Equity RatioN/A Current Ratio12.38 Quick Ratio12.38 Sales & Book Value Annual Sales$90,000.00 Price / Sales5,500.98 Cash FlowN/A Price / Cash FlowN/A Book Value$3.04 per share Price / Book0.95Miscellaneous Outstanding Shares170,720,000Free Float129,237,000Market Cap$495.09 million OptionableOptionable Beta0.90 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Arie S. Belldegrun F.A.C.S. (Age 75)M.D., Co-Founder & Executive Chairman Comp: $649.1kDr. David D. Chang M.D. (Age 64)Ph.D., Co-Founder, President, CEO & Director Comp: $994.6kMr. Joshua A. Kazam (Age 47)Co-Founder & Director Comp: $260.5kMr. Timothy L. Moore Ph.D. (Age 63)Executive VP & Chief Technical Officer Comp: $554.35kDr. Zachary J. Roberts M.D. (Age 46)Ph.D., Executive VP of Research & Development and Chief Medical Officer Comp: $747.39kMr. Geoffrey M. Parker (Age 59)Executive VP & CFO Mr. Earl M. Douglas Esq. (Age 61)Senior VP, General Counsel, Compliance Officer & Corporate Secretary Ms. Susan R. Lundeen (Age 58)Chief People Officer Ms. Christine CassianoExecutive VP, Chief Corporate Affairs & Brand Strategy OfficerYinlin ChenSenior Vice President of FinanceMore ExecutivesKey CompetitorsAlectorNASDAQ:ALECProKidneyNASDAQ:PROKVoyager TherapeuticsNASDAQ:VYGRValnevaNASDAQ:VALNC4 TherapeuticsNASDAQ:CCCCView All CompetitorsInsiders & InstitutionsEntryPoint Capital LLCSold 8,108 shares on 5/14/2024Ownership: 0.017%CANADA LIFE ASSURANCE CoBought 8,162 shares on 5/14/2024Ownership: 0.010%Vanguard Group Inc.Sold 823,261 shares on 5/10/2024Ownership: 4.808%Headlands Technologies LLCBought 17,396 shares on 5/8/2024Ownership: 0.010%SG Americas Securities LLCSold 18,326 shares on 5/7/2024Ownership: 0.021%View All Insider TransactionsView All Institutional Transactions ALLO Stock Analysis - Frequently Asked Questions Should I buy or sell Allogene Therapeutics stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALLO shares. View ALLO analyst ratings or view top-rated stocks. What is Allogene Therapeutics' stock price target for 2024? 8 brokers have issued 1-year price targets for Allogene Therapeutics' stock. Their ALLO share price targets range from $4.60 to $28.00. On average, they expect the company's stock price to reach $12.23 in the next twelve months. This suggests a possible upside of 313.1% from the stock's current price. View analysts price targets for ALLO or view top-rated stocks among Wall Street analysts. How have ALLO shares performed in 2024? Allogene Therapeutics' stock was trading at $3.21 on January 1st, 2024. Since then, ALLO shares have decreased by 7.8% and is now trading at $2.96. View the best growth stocks for 2024 here. When is Allogene Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our ALLO earnings forecast. How were Allogene Therapeutics' earnings last quarter? Allogene Therapeutics, Inc. (NASDAQ:ALLO) announced its earnings results on Monday, May, 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.38). The business had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.01 million. Allogene Therapeutics had a negative net margin of 202,366.25% and a negative trailing twelve-month return on equity of 53.76%. The business's revenue for the quarter was down 26.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.68) earnings per share. What ETFs hold Allogene Therapeutics' stock? ETFs with the largest weight of Allogene Therapeutics (NASDAQ:ALLO) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Direxion Moonshot Innovators ETF (MOON), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Global X Genomics & Biotechnology ETF (GNOM).Horizon Kinetics Medical ETF (MEDX). What is David Chang's approval rating as Allogene Therapeutics' CEO? 2 employees have rated Allogene Therapeutics Chief Executive Officer David Chang on Glassdoor.com. David Chang has an approval rating of 100% among the company's employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Allogene Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP). When did Allogene Therapeutics IPO? Allogene Therapeutics (ALLO) raised $272 million in an IPO on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as the underwriters for the IPO. Who are Allogene Therapeutics' major shareholders? Allogene Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.81%), Mirae Asset Global Investments Co. Ltd. (0.21%), Susquehanna Fundamental Investments LLC (0.17%), Los Angeles Capital Management LLC (0.09%), BNP Paribas Financial Markets (0.04%) and Bourgeon Capital Management LLC (0.03%). Insiders that own company stock include Alison Moore, Arie Belldegrun, David D Chang, Deborah M Messemer, Eric Thomas Schmidt, Geoffrey M Parker, Owen N Witte, Owen N Witte, Rafael Amado, Stephen Mayo and Veer Bhavnagri. View institutional ownership trends. How do I buy shares of Allogene Therapeutics? Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALLO) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe only AI company you should be looking atBehind the MarketsElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.